Statistics at a Glance
At a Glance
Estimated New Cases in 2020 77,240
% of All New Cancer Cases 4.3%
Estimated Deaths in 2020 19,940
% of All Cancer Deaths 3.3%
|Year||Rate of New Cases — SEER 9||Rate of New Cases — SEER 13||Death Rate — U.S.||5-Year Relative Survival — SEER 9|
|Observed||Modeled Trend||Observed||Modeled Trend||Observed||Modeled Trend||Observed||Modeled Trend|
New cases come from SEER 13. Deaths come from U.S. Mortality.
All Races, Both Sexes. Rates are Age-Adjusted.
Modeled trend lines were calculated from the underlying rates using the Joinpoint Trend Analysis Software.
New cases are also referred to as incident cases in other publications. Rates of new cases are also referred to as incidence rates.
Rate of New Cases and Deaths per 100,000: The rate of new cases of non-Hodgkin lymphoma was 19.6 per 100,000 men and women per year. The death rate was 5.5 per 100,000 men and women per year. These rates are age-adjusted and based on 2013–2017 cases and deaths.
Lifetime Risk of Developing Cancer: Approximately 2.1 percent of men and women will be diagnosed with non-Hodgkin lymphoma at some point during their lifetime, based on 2015–2017 data.
Prevalence of This Cancer: In 2017, there were an estimated 719,831 people living with non-Hodgkin lymphoma in the United States.
How Many People Survive 5 Years Or More after Being Diagnosed with Non-Hodgkin Lymphoma?
Relative survival statistics compare the survival of patients diagnosed with cancer with the survival of people in the general population who are the same age, race, and sex and who have not been diagnosed with cancer. Because survival statistics are based on large groups of people, they cannot be used to predict exactly what will happen to an individual patient. No two patients are entirely alike, and treatment and responses to treatment can vary greatly.
Based on data from SEER 18 2010–2016. Gray figures represent those who have died from non-Hodgkin lymphoma. Green figures represent those who have survived 5 years or more.
Survival by Stage
Cancer stage at diagnosis, which refers to extent of a cancer in the body, determines treatment options and has a strong influence on the length of survival. The earlier non-Hodgkin lymphoma is caught, the better chance a person has of surviving five years after being diagnosed. For non-Hodgkin lymphoma, 24.6% are diagnosed at stage I. The 5-year relative survival for stage I non-Hodgkin lymphoma is 83.5%.
|Stage||Percent of Cases||5-Year Relative Survival|
Confined to Single Region
Involving Mulitple Regions
Spread to Both Sides of Diaphragm
Diffuse or Disseminated Involvement
SEER 18 2010–2016, All Races, Both Sexes by Ann Arbor Stage
New Cases and Deaths
How Common Is This Cancer?
Compared to other cancers, non-Hodgkin lymphoma is fairly common.
|Rank||Common Types of Cancer||Estimated New
|1.||Breast Cancer (Female)||276,480||42,170|
|2.||Lung and Bronchus Cancer||228,820||135,720|
|5.||Melanoma of the Skin||100,350||6,850|
|8.||Kidney and Renal Pelvis Cancer||73,750||14,830|
Non-Hodgkin lymphoma represents 4.3% of all new cancer cases in the U.S.
In 2020, it is estimated that there will be 77,240 new cases of non-Hodgkin lymphoma and an estimated 19,940 people will die of this disease.
Who Gets This Cancer?
Non-Hodgkin lymphoma is more common in men than women, and among individuals of Caucasian descent. The rate of new cases of non-Hodgkin lymphoma was 19.6 per 100,000 men and women per year based on 2013–2017 cases, age-adjusted.
|American Indian/Alaska Native||10.8|
|American Indian/Alaska Native||10.9|
SEER 21 2013–2017, Age-Adjusted
|Age Range||Percent of New Cases|
Non-Hodgkin lymphoma is most frequently diagnosed among people aged 65–74.
SEER 21 2013–2017, All Races, Both Sexes
Who Dies From This Cancer?
Non-Hodgkin lymphoma is the eighth leading cause of cancer death in the United States. The death rate was 5.5 per 100,000 men and women per year based on 2013–2017 deaths, age-adjusted.
|American Indian/Alaska Native||5.5|
|American Indian/Alaska Native||3.2|
U.S. 2013–2017, Age-Adjusted
|Age Range||Percent of Deaths|
The percent of non-Hodgkin lymphoma deaths is highest among people aged 75–84.
U.S. 2013–2017, All Races, Both Sexes
Trends in Rates
Changes Over Time
Keeping track of new cases, deaths, and survival over time (trends) can help scientists understand whether progress is being made and where additional research is needed to address challenges, such as improving screening or finding better treatments.
Using statistical models for analysis, age-adjusted rates for new non-Hodgkin lymphoma cases have been falling on average 0.8% each year over the last 10 years. Age-adjusted death rates have been falling on average 2.2% each year over 2008–2017. 5-year relative survival trends are shown below.
More About This Cancer
Figure: This picture shows lymph nodes above and below the diaphragm. It also shows the lymph vessels, tonsils, thymus, and spleen.
Lymphoma is cancer that begins in cells of the lymph system. The lymph system is part of the immune system, which helps the body fight infection and disease. Because lymph tissue is found all through the body, lymphoma can begin almost anywhere.
The two main types of lymphoma are Hodgkin lymphoma and non-Hodgkin lymphoma (NHL). These can occur in both children and adults.
There are many different types of NHL that form from different types of white blood cells (B-cells, T-cells, NK cells). Most types of NHL form from B-cells. NHL may be indolent (slow-growing) or aggressive (fast-growing). The most common types of NHL in adults are diffuse large B-cell lymphoma, which is usually aggressive, and follicular lymphoma, which is usually indolent.
Related Stat Facts by Subtype
- NHL - Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Stat Facts
- NHL - Diffuse Large B-Cell Lymphoma (DLBCL) Stat Facts
- NHL - Follicular Lymphoma Stat Facts
Here are some resources for learning more about non-Hodgkin lymphoma.
- More about risk factors for non-Hodgkin lymphoma
- More about symptoms and diagnosis of non-Hodgkin lymphoma
- More about treatment options for non-Hodgkin lymphoma
- More about clinical trials
- More about cancer prevention
All statistics in this report are based on statistics from SEER and the Centers for Disease Control and Prevention's National Center for Health Statistics. Most can be found within:
Howlader N, Noone AM, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975–2017, National Cancer Institute. Bethesda, MD, https://seer.cancer.gov/csr/1975_2017/, based on November 2019 SEER data submission, posted to the SEER web site, April 2020.
All material in this report is in the public domain and may be reproduced or copied without permission; citation as to source, however, is appreciated.
SEER Cancer Stat Facts: Non-Hodgkin Lymphoma. National Cancer Institute. Bethesda, MD, https://seer.cancer.gov/statfacts/html/nhl.html
These stat facts focus on population statistics that are based on the U.S. population. Because these statistics are based on large groups of people, they cannot be used to predict exactly what will happen to an individual patient. To see tailored statistics, browse the SEER Cancer Statistics Review. To see statistics for a specific state, go to the State Cancer Profiles.
The statistics presented in these stat facts are based on the most recent data available, most of which can be found in the SEER Cancer Statistics Review. In some cases, different year spans may be used. Estimates for the current year are based on past data.
Cancer is a complex topic. There is a wide range of information available. These stat facts do not address causes, symptoms, diagnosis, treatment, follow-up care, or decision making, although links are provided to information in many of these areas.